English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

(HCAR2), HM74A or PUMA-G] is expressed in various cells and tissue types including adipocytes, keratinocytes, immune cells, and epithelial cells (colon and retina) [1,2]. On activation, it regulates metabolic and immune signaling in various cell types. Despite the essential role of GPR109A receptor as a metabolic sensor, its expression and function in the liver was not fully understood until recently. In fact, several earlier studies reported that the receptor was not expressed at all in the liver [1] or, that is expressed in the tissue but only minimally [3]. In keeping with the long-standing interest of our research group in understanding GPR109A signaling, in one of our recent studies, we examined GPR109A expression in normal human and mouse livers and in various liver cell types [4]. We also evaluated the impact of GPR109A deletion on ageassociated hepatic steatosis. We found GPR109A to be expressed in human and mouse liver tissues, with Kupffer cells displaying the highest level of expression. Importantly, we additionally demonstrated hepatic GPR109A expression to decline with age in mice a phenomenon that we speculated might contribute to increase fat accumulation in aging. This we confirmed using GPR109A-/mice, and indeed we saw that loss of expression of GPR109A was correlated with the enhanced accumulation of visceral and hepatic fat in aged mice [4]. Our findings collectively provided extensive evidence for GPR109A expression in hepatocytes/liver and its importance in controlling de novo lipogenesis in liver and adipose tissue of aging mice. A few years after the first report on niacin’s lipid lowering efficacy, GPR109A was identified as its receptor. Since then the use of niacin to treat dyslipidemia has been well documented. While, some of these studies showed involvement of GPR109A, others reported GPR109A independent effects [5]. Recently, a study by Ye et al., 2019 provided further evidence that GPR109A is expressed in liver and hepatocytes [6]. They additionally showed that niacin-induced GPR109A signaling fine-tunes lipid metabolism through various mechanisms, including the inhibition of hepatocyte lipogenesis and fatty acid intake, and the promotion of brown adipose tissue thermogenesis. Although, initial studies concluded that niacin’s positive effects on lipid metabolism are independent of GPR109A, studies by Editorial

GPR109A activation and aging liver